Details for Patent: 9,220,707
Which drugs does patent 9,220,707 protect, and when does it expire?
Patent 9,220,707 protects SOFDRA and is included in one NDA.
This patent has thirty-seven patent family members in twenty-one countries.
Summary for Patent: 9,220,707
| Title: | Method of dosing and use of soft anticholinergic esters | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | A method of treating hyperhidrosis in a mammalian subject comprising: and | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Nicholas S. Bodor, David Angulo | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Bodor Laboratories Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/213,242 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 9,220,707: Scope, Claims, Expiration, Orange Book Status, and Sofpironium Patent LandscapeUS Patent 9,220,707 covers topical treatment and dosing of hyperhidrosis with specific quaternary ammonium anticholinergic compounds, principally sofpironium bromide. The claims require a defined chemical structure, 1% to 25% concentration, bedtime application, at least 25% sweat reduction for six hours, efficacy comparable to topical glycopyrrolate, and an improved safety profile. The patent was granted on December 29, 2015, and has a nominal expiration date in March 2033, subject to any applicable patent-term adjustment or terminal disclaimer. The patent is commercially relevant to Sofdra, the sofpironium bromide topical gel approved by the FDA in 2024 for primary axillary hyperhidrosis in patients aged nine years and older. The strongest practical protection is concentrated in the active-ingredient genus, stereochemical variants, concentration range, bedtime dosing, and comparative safety and efficacy limitations. What drug and technology does US Patent 9,220,707 protect?The patent protects topical use of pyrrolidinium bromide compounds related to glycopyrrolate but structurally modified with an alkoxycarbonylmethyl substituent. The principal commercial compound is sofpironium bromide, also known as BB-4000 or BB-4010 in development materials. Its chemical name is generally represented as: 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(methoxycarbonylmethyl)-1-methylpyrrolidinium bromide. The claimed compounds have:
The patent is therefore broader than a claim limited to a single commercial stereoisomer or a single formulation. It reaches specified stereochemical mixtures and both methyl and ethyl variants. What are the independent claims in US 9,220,707?Claims 1 and 9 are the two independent claims.
Both independent claims require:
The duplication of claims 1 and 9 creates two infringement theories. Claim 1 is directed to treatment. Claim 9 is directed to dosing. In practice, both claims would likely be asserted against a product or regimen using the claimed compound for hyperhidrosis. How broad is the chemical scope of the patent?The chemical scope is materially broader than sofpironium bromide alone. Claim 1 covers compounds in which:
Claim 7 lists 16 named compounds or stereochemical variants. Claims 15 and 16 repeat the same compound coverage under the dosing-method branch. This structure creates several layers of protection:
A product using the same active ingredient but a different dosage form could still fall within the claims because the formulation language is expansive. What formulations are protected by US Patent 9,220,707?The dependent claims cover nearly every conventional topical dosage form. Claimed formulations include:
The claims specifically identify compositions containing approximately 2% to 10% of the compound and a 5% solution in 70% ethanol. Claims 25 through 36 extend the solvent coverage to:
The formulation coverage is therefore not limited to the commercial Sofdra gel. A competing product could face exposure even if it uses an alcohol solution, cream, foam, or lotion rather than a gel. Does the patent cover Sofdra?The claims appear directed to the active ingredient and treatment regimen used for Sofdra. Sofdra is a 12.45% topical gel containing sofpironium bromide and is indicated for primary axillary hyperhidrosis. The commercial product is administered topically, generally once daily in the evening, consistent with the claimed bedtime regimen. The FDA approved Sofdra on June 18, 2024, under NDA 214697 for patients nine years of age and older.[2] The commercial concentration is above the 1% minimum and within the broad 1% to 25% range in claims 1 and 9. It is also within the 2% to 10% range only if concentration is expressed on a different active-equivalent or formulation basis. The commercial formulation should therefore be evaluated against the precise concentration convention used in the patent and product labeling. When does US Patent 9,220,707 expire?The patent was granted on December 29, 2015. Its nominal term is generally calculated from the earliest effective nonprovisional or PCT filing date, not from the grant date. Based on the reported March 15, 2013 filing date, the nominal expiration date is March 15, 2033, before any patent-term adjustment.[1]
The provisional priority date generally does not determine the 20-year patent term. A final freedom-to-operate analysis should use the USPTO patent-term calculation, including any patent-term adjustment and terminal disclaimer information. What is the Orange Book status of US 9,220,707?US Patent 9,220,707 is relevant to the approved Sofdra product and has been treated in public drug-patent materials as a core patent for sofpironium bromide hyperhidrosis treatment. FDA Orange Book treatment depends on the patent’s listing against the specific NDA and dosage form. Method-of-use patents can be listed when they claim an approved use. The commercial significance of an Orange Book listing is substantial:
The Orange Book listing should be distinguished from the patent’s underlying validity. Listing is an FDA regulatory act and does not establish that the patent would survive an invalidity or infringement challenge. What Paragraph IV challenges and generic entry risks exist?The provided record does not identify a filed Paragraph IV challenge or a completed generic litigation proceeding involving US 9,220,707. The patent’s remaining term creates a substantial barrier to a conventional generic launch before 2033 unless a challenger succeeds in litigation, obtains a settlement permitting earlier entry, or uses a noninfringing regulatory strategy. A generic applicant would likely assess the following vulnerabilities: Comparative-result limitationsThe claims require efficacy substantially equivalent to topical glycopyrrolate and an improved safety profile. These limitations may create proof issues because infringement would require comparative clinical or pharmacological evidence. The same limitations can also create validity questions. A challenger could argue that the terms "substantially equivalent" and "improved safety profile" lack objective boundaries or are insufficiently supported across the full claimed chemical and formulation scope. Bedtime administrationA product label that directs administration at another time could create a noninfringement position. That defense would depend on actual use, labeling language, induced infringement evidence, and whether patients routinely administer the product before bedtime. Concentration and active-ingredient identityA formulation outside the 1% to 25% concentration range, or a compound outside the claimed stereochemical and structural genus, could avoid literal infringement. The doctrine of equivalents could still be relevant, particularly for close stereochemical or ester substitutions. Indication carve-outsA generic seeking treatment of a different sweating condition might attempt to avoid the patented hyperhidrosis use. That strategy would be commercially limited if most foreseeable use remained the patented indication. How strong is the patent estate for sofpironium?US 9,220,707 is strong at the regimen level but less secure at the functional-limitation level.
The patent’s commercial strength comes from the combination of chemical and method limitations. A competitor would need to avoid more than one limitation to reduce risk. What patent litigation affects sofpironium and hyperhidrosis products?The principal competitive products are:
No specific completed Paragraph IV settlement or final infringement judgment is established by the supplied claim record. Licensing and patent ownership should be separated from litigation status. What licensing deals affect the patent landscape?Sofpironium was developed through a relationship involving Kaken Pharmaceutical and Brickell Biotech. Kaken developed the compound in Japan, where sofpironium bromide was approved as Ecclock for primary axillary hyperhidrosis. Brickell obtained rights to develop and commercialize the product in specified territories, including the United States.[3] The commercial license matters because patent enforcement may involve:
The licensing arrangement does not itself expand the scope of US 9,220,707. It affects who controls enforcement and commercialization. How does US 9,220,707 compare with glycopyrrolate patents?US 9,220,707 is not a conventional glycopyrrolate patent. It uses glycopyrrolate as a comparator and claims structurally related anticholinergic compounds.
This distinction matters because a competitor may avoid US 9,220,707 by using glycopyrronium itself, but that product may face separate Orange Book patents covering Qbrexza or another glycopyrronium formulation. What manufacturing and IP barriers exist?The patent does not claim a manufacturing process in the provided claims. Its main barrier is use of the compound in a covered topical regimen, not synthesis. Manufacturing risks may still arise from:
A manufacturer could avoid process infringement under this patent while still facing method-of-use exposure when its product is marketed for hyperhidrosis. What generic launch scenarios are most likely?Three launch scenarios are commercially relevant. Early negotiated entryA generic applicant could challenge the patent and settle for an agreed launch date before March 2033. The settlement could include restrictions based on product labeling, formulation, or indication. Litigation-driven entryA Paragraph IV filing could lead to patent litigation and a 30-month stay. Early launch would depend on invalidity, noninfringement, or a court ruling that the Orange Book listing does not block approval. Post-expiration entryAbsent a successful challenge or settlement, broad generic entry is most likely after the patent term ends. A generic could then compete through a gel, solution, cream, foam, or other topical formulation, subject to FDA requirements for the applicable abbreviated pathway. Key Takeaways
FAQsIs US Patent 9,220,707 a composition patent?No. The supplied claims are method claims. They protect using specified compounds in topical hyperhidrosis treatment and dosing, rather than claiming the compound composition in the abstract. Does the patent cover oral sofpironium bromide?No. The claims require topical administration to skin affected by hyperhidrosis. Oral administration would not satisfy the express topical-use limitation. Does a 12.45% sofpironium product fall within the patent?It falls within the broad 1% to 25% concentration range, subject to the precise active-ingredient, formulation, bedtime, efficacy and safety limitations of the claims. Can a competitor avoid the patent by using a cream instead of a gel?Not necessarily. The claims expressly include creams and multiple other topical dosage forms. Changing the dosage form alone may not avoid infringement. Does FDA approval prove that the patent is valid?No. FDA approval and Orange Book listing are regulatory events. Patent validity remains subject to judicial review, including anticipation, obviousness, written description, enablement, indefiniteness and other defenses. References
More… ↓ |
Drugs Protected by US Patent 9,220,707
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,220,707
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014227923 | ⤷ Start Trial | |||
| Brazil | 112015023153 | ⤷ Start Trial | |||
| Canada | 2904724 | ⤷ Start Trial | |||
| China | 105050596 | ⤷ Start Trial | |||
| China | 109364066 | ⤷ Start Trial | |||
| Denmark | 2968267 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
